prikaz prve stranice dokumenta Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
  Preuzmi
PDF 452.25 KB
Znanstveni rad - Prikaz slučaja
Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
Monaldi Archives for Chest Disease, 89 (2019), 2; https://doi.org/10.4081/monaldi.2019.1023
Hećimović, Ana; Vukić Dugac, Andrea; Janković Makek, Mateja; Čikeš, Maja; Samaržija, Miroslav; Jakopović, Marko

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Hećimović, A., Vukić Dugac, A., Janković Makek, M., Čikeš, M., Samaržija, M. i Jakopović, M. (2019). Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient. Monaldi Archives for Chest Disease, 89. (2). doi: 10.4081/monaldi.2019.1023

Hećimović, Ana, et al. "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient." Monaldi Archives for Chest Disease, vol. 89, br. 2, 2019. https://doi.org/10.4081/monaldi.2019.1023

Hećimović, Ana, Andrea Vukić Dugac, Mateja Janković Makek, Maja Čikeš, Miroslav Samaržija i Marko Jakopović. "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient." Monaldi Archives for Chest Disease 89, br. 2 (2019). https://doi.org/10.4081/monaldi.2019.1023

Hećimović, A., et al. (2019) 'Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient', Monaldi Archives for Chest Disease, 89(2). doi: 10.4081/monaldi.2019.1023

Hećimović A, Vukić Dugac A, Janković Makek M, Čikeš M, Samaržija M, Jakopović M. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient. Monaldi Archives for Chest Disease [Internet]. 30.05.2019. [pristupljeno 26.12.2024.];89(2). doi: 10.4081/monaldi.2019.1023

A. Hećimović, A. Vukić Dugac, M. Janković Makek, M. Čikeš, M. Samaržija i M. Jakopović, "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient", Monaldi Archives for Chest Disease, vol. 89, br. 2, Svibanj 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:233301. [Citirano: 26.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:233301
Podaci o radu
Naslov (engleski)Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
AutorAna Hećimović
AutorAndrea Vukić Dugac
AutorMateja Janković Makek
AutorMaja Čikeš
AutorMiroslav Samaržija
AutorMarko Jakopović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Lung cancer incidence in heart transplant patients is higher than in general population and correlates with smoking history. EGFR-mutations are more frequent in adenocarcinoma and among non-smoking women but incidence in solid organ transplanted patients is still not known. We present case of a 65-yearold ex-smoker male with history of heart transplantation and EGFR positive metastatic lung adenocarcinoma. At admission he was in a severe clinical condition and treatment with erlotinib was started. Initially he had good clinical and radiologic response to treatment with only grade 1 side effects. Data about drug interactions between cyclosporine and erlotinib are insufficient but we have to take this interaction into consideration during treatment because both drugs are substrates and inhibitors of CYP34A. In our case erlotinib was safe and well tolerated drug, there were no relevant toxicity, but close monitoring and dose reduction of cyclosporine was needed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMonaldi Archives for Chest Disease
Brojčani podacivol. 89, br. 2
p-ISSN1122-0643
DOIhttps://doi.org/10.4081/monaldi.2019.1023
URN:NBNurn:nbn:hr:105:233301
Datum objave publikacije2019-05-30
URL dokumentahttp://doi.org/10.4081/monaldi.2019.1023
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:32:48